Impact of dosing regimen of custirsen, an antisense oligonucleotide, on safety, tolerability and cardiac repolarization in healthy subjects

British Journal of Clinical Pharmacology
Laura Rabinovich-GuilattOfer Spiegelstein

Abstract

Custirsen (OGX-011/TV-1011), a second-generation antisense oligonucleotide (ASO) that reduces clusterin production, is under investigation with chemotherapy in patients with solid tumours. Custirsen is associated with constitutional symptoms (CS) that may interfere with clinical pharmacology investigations, such as QT interval studies. Experience with other ASOs suggests NSAID premedication may ameliorate CS, but we observed suboptimal outcomes in healthy subjects given custirsen and NSAIDs. We sought to establish a custirsen regimen for future clinical pharmacology studies in healthy subjects. Subjects received custirsen (640 mg intravenously over 120 min) with dexamethasone premedication or increasing doses (320, 480, 640 mg over 6 days) of custirsen with dexamethasone premedication, then one full custirsen dose without premedication on day 8. Incidence/severity of adverse events (AEs) and extensive electrocardiogram readings were evaluated. Pharmacokinetic parameters were estimated. AEs included CS, elevated transaminases and prolonged activated partial thromboplastin time (aPTT) that were predominantly grade 1/2. Administration of increasing custirsen doses and dexamethasone premedication reduced the incidence of CS associa...Continue Reading

References

Nov 5, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J NemunaitisS G Eckhardt
Nov 20, 2002·The Journal of Pharmacology and Experimental Therapeutics·K Lea SewellF Andrew Dorr
Nov 2, 2004·Familial Cancer·Jose G GuillemNathan A Ellis
Oct 6, 2005·International Journal of Urology : Official Journal of the Japanese Urological Association·Hideaki MiyakeMartin E Gleave
Feb 14, 2007·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Bruce YacyshynEmil Chuang
Feb 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kim N ChiElizabeth Eisenhauer
Jun 14, 2008·The Journal of Clinical Investigation·Ahmad S AminArthur A M Wilde
Nov 18, 2008·Expert Opinion on Investigational Drugs·Kim N ChiMartin E Gleave
Sep 10, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Marc T AbramsLaura Sepp-Lorenzino
Jan 9, 2010·Annual Review of Pharmacology and Toxicology·C Frank Bennett, Eric E Swayze
Feb 11, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amina ZoubeidiMartin Gleave

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.